Methods of treating depression and other related diseases

• US 9,340,576 B2
• Filed: 06/04/2013
• Issued: 05/17/2016
• Est. Priority Date: 10/05/2009
• Status: Active Grant

• Current Assignee: Northwestern University
• Original Assignee: Northwestern University
• Inventors: Moskal, Joseph
• Primary Examiner(s): JEAN-LOUIS, SAMIRA JM
• Application Number:
  US13/909,712
• Publication Number:
  US 20130288975A1
• Time in Patent Office: 1,078 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: C07K 5/06139 with the first amino acid being heterocyclic
• CPC Class Codes: C07K 5/081 the side chain containing O or S as heteroatoms, e.g. Cys, Ser
• CPC Class Codes: C07K 5/0821 with the first amino acid being heterocyclic, e.g. His, Pro, Trp
• CPC Class Codes: C07K 5/1013 the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Abstract

The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.

Claims

1. A method for treating dysthymic disorder in a patient in need thereof, comprising administering to said patient a 1 mg/kg to about 10 mg/kg dose of a compound represented by:

2. The method of claim 1, comprising administering the composition every week or every two weeks to said patient.

3. The method of claim 1, wherein administration of a single dose is effective for up to 4 days.

4. The method of claim 1, further comprising administering another antidepressant drug.

5. he method of claim 2, further comprising administering another antidepressant drug.

6. A method for treating dysthymic disorder in a patient in need thereof, comprising administering to said patient a pharmaceutically acceptable composition comprising:

a 1 mg/kg to about 10 mg/kg dose of a compound represented by;

7. A method for treating dysthymic disorder in a patient in need thereof, comprising administering to said patient a 1 mg/kg to about 10 mg/kg dose of a compound represented by: